Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program [Yahoo! Finance]
Marker Therapeutics, Inc. (MRKR)
Last marker therapeutics, inc. earnings: 11/12 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
OTS product was well tolerated - safety data consistent with other MAR-T cell studies HOUSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the first patient has been treated in the Company's OTS program, with encouraging preliminary safety data. Marker is evaluating the safety and efficacy of escalating doses of MT-401, a multi-antigen recognizing (MAR) T cell product targeting four antigens, as an OTS product in the Phase 1 RAPID study (clinicaltrials.gov Identifier: NCT06552416). The first study participant received the OTS product at the initial dose level (100x10 cells) and was monitored for 28 days. The therapy was well tolerated with no treatment-related adverse events. This observation is consistent with the favorable safety profile and t
Show less
Read more
Impact Snapshot
Event Time:
MRKR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRKR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRKR alerts
High impacting Marker Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRKR
News
- Marker Therapeutics (NASDAQ:MRKR) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MRKR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Marker Therapeutics (NASDAQ:MRKR) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire
- Marker Therapeutics appoints Kathryn Penkus Corzo to Board of DirectorsGlobeNewswire
MRKR
Sec Filings
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- MRKR's page on the SEC website